NCT07045701 - FMXIN002 in Patients at Risk of Anaphylaxis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 12, 2025

Primary Completion Date

June 12, 2026

Study Completion Date

July 12, 2026

Conditions

Anaphylaxis Food

Interventions

COMBINATION_PRODUCT

Epinephrine 4mg nasal powder spray

Epinephrine nasal powder spray in a unidose nasal applicator device. Will be administered together with a placebo saline IM injection

COMBINATION_PRODUCT

Adrenalin 0.5mg Injectable Product

Epinephrine 0.5mg for IM injection. Will be administered together with a placebo nasal powder spray.

Trial Locations (1)

Shamir Medical Center, Be’er Ya‘aqov